Research into the treatment of patients with a malignant brain tumor (glioblastoma) will be able to progress thanks to generous funding by the Dutch Cancer Society (KWF). Annually, approximately 800 adults are diagnosed in the Netherlands and despite intensive therapies these patients are confronted with a progressive loss of quality-of-life and no chance of cure. Better, more efficacious treatments are therefore dearly needed.
A research team led by Olaf van Tellingen, Leila Akkari, and Mark de Gooijer is currently working on the development of new treatments for glioblastoma. Olaf van Tellingen: “Our team has discovered new combinations of drugs that force the glioblastoma cells to permanently stop dividing. We will now be able to search for the most effective drug combinations that are also most likely to work in our patients.” The research team expects their research will ultimately lead to a clinical trial in patients.
Related content
Nine Netherlands Cancer Institute research groups to receive Dutch Cancer Society funding